Our focus today will be on our T cell receptor or TCR replacement approach for our wholly owned acute myeloid leukemia or AML program. As a reminder, Intellia's TCR replacement approach knocks out the endogenous TCR by eliminating the alpha and beta chains and inserts their therapeutic TCR in locus.